CoreValve Evolut R CE: Good results at 6 months of the new CoreValve repositionable

This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve.

All maneuvers were carried out successfully. A 30 days no deaths or stroke were observed, with a rate of severe aortic regurgitation of 3.4% and the need for permanent pacemaker 11.7%.

Conclusion

Evolut R CoreValve security and system performance were established, repositioning was well tolerated when necessary, with low rate of severe aortic regurgitation and decreased need for permanent pacemaker.

Ian Meredith
2015-05-20

Original title: 6-month outcomes following TAVI with a novel repositionable self-expanding bioprosthesis – CoreValve Evolut R CE Study.

More articles by this author

NONSTEMI: Superiority of early angioplasty in non-ST elevation myocardial infarction

The European guidelines recommend revascularization within 24 hours in high-risk patients with No ST segment elevation myocardial infarction. It is unclear whether these patients...

TOTAL stroke: increased risk of stroke with thromboaspiration

There are many doubts about the benefit of manual thromboaspiration, not only in terms of improvement of the clinical end point but also the...

PARTNER II: Less oversizing to reduce paravalvular failure with the new generation of SAPIEN 3

The new generation SAPIEN 3 valve was designed to reduce paravalvular aortic regurgitation. The objective of this work was to evaluate the influence of...

IN.PACT Global Study: Pharmacological balloon in long lesions of the Superficial Femoral Artery (SFA)

Long lesions (≥ 15 cm), total occlusions, and in-stent restenosis represent a unique treatment challenge in peripheral vascular disease. IN.PACT Global study is a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...